GlassScriptPhysician profile
Robert Scott Hammond
NPI 1295769354
$190.12
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $43.55 · 2022: $16.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.69 | 2019 | |
| Sanofi Pasteur INC. | $18.03 | 2019 | |
| Hologic Sales and Service, LLC | $17.65 | 2020 | |
| Amgen INC. | $17.60 | 2019 | |
| Novo Nordisk INC | $17.08 | 2019 | |
| Abbvie INC. | $16.81 | 2022 | |
| Glaxosmithkline, LLC. | $16.15 | 2019 | |
| Seqirus USA INC | $13.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.22 | 2019 | |
| Pfizer INC. | $12.87 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.